Differential effects of lipophilic and hydrophilic statins on muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction.
This study was conducted as a prospective, randomized, open-label, crossover trial. Ten HFpEF patients with untreated hyperlipidemia participated in this study. Subjects were assigned to either the atorvastatin (lipophilic) or the rosuvastatin (hydrophilic) group with each drug administered for 8 weeks. Atorvastatin and rosuvastatin treatment resulted in a similar reduction in low-density lipoprotein cholesterol (LDL-C) levels. There was no difference in the effect of either treatment on blood pressure, heart rate, or left ventricular function. Atorvastatin significantly decreased MSNA frequency compared with baseline (31.5 ± 6.3 vs. 47.5 ± 10.7 bursts/min, p < 0.01), but rosuvastatin had no effect on MSNA (40.9 ± 7.3 bursts/min). MSNA was significantly lower in the atorvastatin group than rosuvastatin group (p < 0.05). However, the reduction in MSNA seen in either group did not correlate with the reduction in LDL-C. No significant differences were observed in either the baroreflex control of heart rate or MSNA between the two groups. These results suggest that lipophilic statins have a favorable effect on sympathetic nerve activity beyond lowering LDL-C in HFpEF, but hydrophilic statins do not.
PMID: 30005743 [PubMed - in process]
Source: Autonomic Neuroscience - Category: Neuroscience Authors: Tokuhisa H, Murai H, Okabe Y, Hamaoka T, Sugimoto H, Mukai Y, Inoue O, Takashima SI, Kato T, Usui S, Furusho H, Kaneko S, Takamura M Tags: Auton Neurosci Source Type: research
More News: Atorvastatin Calcium | Brain | Cardiology | Cholesterol | Crestor | Heart | Heart Failure | Lipitor | Neurology | Reflex Sympathetic Dystrophy | Rosuvastatin | Statin Therapy | Study | Zivast